2. Search Result
Search Result
Results for "

and hCA XII

" in MedChemExpress (MCE) Product Catalog:

54

Inhibitors & Agonists

1

Natural
Products

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-162063
    hCAIX/XII-IN-9

    		Carbonic Anhydrase Inflammation/Immunology Cancer
    hCAIX/XII-IN-9 (compound 8) is a potent carbonic anhydrase (CA) inhibitor with Ki values of 1658 nM, 184.8 nM, 8.9 nM, 64.8 nM for hCA I, hCA II, hCA IX, and hCA XII, respectively .
    hCAIX/XII-IN-9
  • HY-149402
    hCA XII-IN-6

    		Carbonic Anhydrase Cancer
    hCA XII-IN-6 (compound 4d) is a potent hCA XII inhibitor with a Ki value of 84.2 nM. hCA XII-IN-6 has anti-proliferative activity. hCA XII-IN-6 can be used in research of cancer .
    hCA XII-IN-6
  • HY-156169
    hCAIX/XII-IN-7

    		Carbonic Anhydrase Cancer
    hCAIX/XII-IN-7 (compound 3e) is a potent hCA IX and XII inhibitor with Kis of 3.2 nM, 9.2 nM, 503.7 nM and 59 nM for hCA I, hCA II, hCA IX and hCA XII, respectively. hCAIX/XII-IN-7 has the potential for hypoxic tumors research .
    hCAIX/XII-IN-7
  • HY-147799
    hCA XII/II/IX-IN-1

    		Carbonic Anhydrase Cancer
    hCA XII/II/IX-IN-1 (Compound 3) is a potent human carbonic anhydrase (hCA) inhibitor with IC50 values of 2.6, 0.004, 0.005 and 0.001 μM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA XII/II/IX-IN-1 shows anticancer activity .
    hCA XII/II/IX-IN-1
  • HY-147828
    hCAIX-IN-11

    		Carbonic Anhydrase Cancer
    hCAIX-IN-11 (Compound 5d) is a selective carbonic anhydrase IX and XII inhibitor with Ki s of 32.7 and 623.5 nM for hCA IX and hCA XII, respectively.  hCA IX and hCA XII are transmembrane isoforms which have been characterized as biomarkers for several types of tumors. The hCA XII assists in maintenance of acid-base homoeostasis in normal as well as tumor cells .
    hCAIX-IN-11
  • HY-147827
    hCAIX-IN-10

    		Carbonic Anhydrase Cancer
    hCAIX-IN-10 (Compound 6i) is a selective carbonic anhydrase IX and XII inhibitor with Ki s of 61.5 and 586.8 nM for hCA IX and hCA XII, respectively.  hCA IX and hCA XII are transmembrane isoforms which have been characterized as biomarkers for several types of tumors. The hCA XII assists in maintenance of acid-base homoeostasis in normal as well as tumor cells .
    hCAIX-IN-10
  • HY-146979
    hA2A/hCA XII modulator 1

    		Adenosine Receptor Carbonic Anhydrase Cancer
    hA2A/hCA XII modulator 1 (compound 14), a triazolopirazine, is a potent hA2A adenosine receptor (hA2AAR) antagonist with Kis of 6.4 nM, 4.819 μM, >30 μM for hA2AAR, hA1AR, hA3AR, respectively. hA2A/hCA XII modulator 1 is a potent human carbonic anhydrase XII (hCA XII) inhibitor with Kis of 6.2 nM, 46 nM, 466 nM, 8.351 μM for hCA XII, hCA II, hCA IX and hCA I, respectively. hA2A/hCA XII modulator 1 has the potential for cancer research .
    hA2A/hCA XII modulator 1
  • HY-163414
    hCAIX/XII-IN-11

    		Carbonic Anhydrase Cancer
    hCAIX/XII-IN-11 (Compound 6c) is an inhibitor of hCA IX and hCA XII with a Ki value of 0.7 μM for both the isoforms. hCAIX/XII-IN-11 can be used for anticancer research .
    hCAIX/XII-IN-11
  • HY-147829
    hCAXII-IN-2

    		Carbonic Anhydrase Cancer
    hCAXII-IN-2 (compound 5i) is a potent human carbonic anhydrase XII (hCA XII) and hCA IX inhibitor with Ki values of 84.2 nM and 268.5 nM, respectively. hCAXII-IN-2 shows less active against hCA I and hCA II .
    hCAXII-IN-2
  • HY-150695
    hCAIX/XII-IN-5

    		Carbonic Anhydrase Apoptosis Cancer
    hCAIX/XII-IN-5 (Coumarin 9a) a carbonic anhydrase (CA) inhibitor, and exhibits excellent hCA IX/XII selectivity (Ki=93.9 and 85.7 nM, respectively) over hCA I and hCA II. hCAIX/XII-IN-5 shows anti-proliferative activities to cancer cells. hCAIX/XII-IN-5 can delay cell cycle and induce apoptosis .
    hCAIX/XII-IN-5
  • HY-143460
    CAXII-IN-1

    		Carbonic Anhydrase Cancer
    CAXII-IN-1 (Compound 17) is a selective CA XII inhibitor with Ki values of 3.8 nM and 56.0 nM against hCA XII and hCA IX, respectively. CAXII-IN-1 shows antitumor activity .
    CAXII-IN-1
  • HY-163710
    hCA/VEGFR-2-IN-5

    		VEGFR Carbonic Anhydrase Cancer
    hCA/VEGFR-2 IN-5 (compound 9) is an indolone-phenylsulfonamide and a potential dual inhibitor of cancer-related hCA IX/XII and VEGFR-2. The IC50 values of hCA/VEGFR-2-IN-5 for VEGFR-2, hCA IX and hCA XII are 0.38 μM, 40 and 3.2 nM, respectively. hCA/VEGFR-2-IN-5 has antitumor activity .
    hCA/VEGFR-2-IN-5
  • HY-155694
    hCA/VEGFR-2-IN-1

    		Carbonic Anhydrase VEGFR Cancer
    hCA/VEGFR-2-IN-1 (compound 13a) is a potent dual Carbonic Anhydrase(CA) IX/XII with Ki values of 4.7 nM and 8.3 nM for hCA XII and hCA IX, respectively. hCA/VEGFR-2-IN-1 (compound 13a) is a potent VEGFR-2 inhibitor with IC50 values 26.3 nM. hCA/VEGFR-2-IN-1 has anticancer activity .
    hCA/VEGFR-2-IN-1
  • HY-155760
    hCA/VEGFR-2-IN-3

    		VEGFR Carbonic Anhydrase Cancer
    hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-3 inhibits VEGFR-2 (IC50=358 nM), has high binding activity to hCAs with Ki of 4.2 nM (hCA IX), 22.9 nM (hCA II), 25.1 nM (hCA I), 28.0 nM (hCA XII), respectively. hCA/VEGFR-2-IN-3 has antiproliferative activity against VEGFR-2 overexpressing breast cancer cells .
    hCA/VEGFR-2-IN-3
  • HY-144639
    Carbonic anhydrase inhibitor 5

    		Carbonic Anhydrase Infection Inflammation/Immunology Cancer
    Carbonic anhydrase inhibitor 5 is a potent and selective human carbonic anhydrase (hCA) inhibitor with IC50s of 42.9, 47,6 and 6.7 nM for hCA II, hCA IX and hCA XII, respectively .
    Carbonic anhydrase inhibitor 5
  • HY-146355
    hCAII-IN-2

    		Carbonic Anhydrase Cancer
    hCAII-IN-2 (Compound 11f) is a cytosolic human carbonic anhydrase (hCA) inhibitor with Ki values of 261.4, 3.8, 19.6 and 45.2 nM against hCA I, hCA II, hCA IX and hCA XII, respectively .
    hCAII-IN-2
  • HY-144641
    Carbonic anhydrase inhibitor 7

    		Carbonic Anhydrase Cancer
    Carbonic anhydrase inhibitor 7 (compound 5b) is a potent inhibitor of human carbonic anhydrase (hCA), with Kis of 6.5 nM, 7.1 nM, 72.1 nM, and 255.8 nM for hCA IX, hCA II, hCA XII and hCA I, respectively .
    Carbonic anhydrase inhibitor 7
  • HY-144640
    Carbonic anhydrase inhibitor 6

    		Carbonic Anhydrase Cancer
    Carbonic anhydrase inhibitor 6 (compound 9b) is a potent inhibitor of human carbonic anhydrase (hCA), with Kis of 9.7 nM, 35.2 nM, 88.5 nM, and 91.8 nM for hCA IX, hCA II, hCA XII and hCA I, respectively .
    Carbonic anhydrase inhibitor 6
  • HY-156181
    hCAIX/XII-IN-8

    		Carbonic Anhydrase Cancer
    hCAIX/XII-IN-8 (compound 3g) is a potent human (carbonic anhydrase) CA IX and XII inhibitor, with Ki values of 8.5 and 6.7 nM, respectively. hCAIX/XII-IN-8 shows particularly strong inhibitory activity against the tumor-associated membrane-bound isoforms, hCA IX and XII, while maintaining a high selectivity ratio over cytosolic off-target isoforms hCA I and II .
    hCAIX/XII-IN-8
  • HY-146206
    HCAIX-IN-1

    		Carbonic Anhydrase Cancer
    HCAIX-IN-1 (compound 21e) is a potent and selective HCAIX inhibitor with KIs of 694.9, 126.6, 3.3, 9.8 nM for hCA I, hCA II, hCA IX, hCA XII, respectively .
    HCAIX-IN-1
  • HY-132156
    Carbonic anhydrase inhibitor 22

    		Carbonic Anhydrase Neurological Disease
    Carbonic anhydrase inhibitor 22 (Compd 2g), a sulfonamide carbonic anhydrase inhibitor, with Ki values of 762 nM (hCA I), 20.3 nM (hCA II), 8.3 nM (hCA VII), 17.9 nM (hCA IX) and 10.5 nM (hCA XII), repectively .
    Carbonic anhydrase inhibitor 22
  • HY-155758
    hCA/VEGFR-2-IN-2

    		VEGFR Carbonic Anhydrase Cancer
    hCA/VEGFR-2-IN-2 (compound 8g) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-2 inhibits VEGFR-2 (IC50=204 nM) and has high binding activity to hCAs, with Kis of 3.6 nM (hCA IX), 16.1 nM (hCA II), 16.7 nM (hCA XII), and 75.3 nM (hCA I), respectively. hCA/VEGFR-2-IN-2 has antiproliferative activity on VEGFR-2-overexpressing breast cancer cells .
    hCA/VEGFR-2-IN-2
  • HY-155763
    hCA/VEGFR-2-IN-4

    		VEGFR Carbonic Anhydrase Cancer
    hCA/VEGFR-2-IN-4 (compound 15b) is an indolinylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-4 inhibits VEGFR-2 (IC50=0.811 μM) and has high binding activity to hCAs, with Ki of 3.8 nM (hCA XII), 6.2 nM (hCA IX), 19.8 nM (hCA II), and 35.5 nM (hCA I), respectively. hCA/VEGFR-2-IN-4 has antiproliferative activity on VEGFR-2-overexpressing breast cancer cells .
    hCA/VEGFR-2-IN-4
  • HY-146007
    hCAIX-IN-17

    		Carbonic Anhydrase Cancer
    hCA IX-IN-1 (Compound 6f) is a human carbonic anhydrase (hCA) inhibitor with Ki values of 331.4, 28.4, 9.4 and 17.8 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA IX-IN-1 shows anticancer activity .
    hCAIX-IN-17
  • HY-146008
    hCAII-IN-3

    		Carbonic Anhydrase Cancer
    hCAII-IN-3 (Compound 16) is a human carbonic anhydrase (hCA) inhibitor with Ki values of 403.8, 5.1, 10.2 and 5.2 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA IX-IN-2 shows anticancer activity .
    hCAII-IN-3
  • HY-132155
    Indan-5-sulphonamide

    NSC 91508

    		 Carbonic Anhydrase Neurological Disease
    Indan-5-sulphonamide (Compd 1) is a carbonic anhydrase inhibitor and anticonvulsant agent, with Ki values of 0.039 nM (hCA XII), 6.5 nM (hCA XIV) and 5.1 nM (hCA XIV), respectively .
    Indan-5-sulphonamide
  • HY-146207
    HCAIX-IN-2

    		Carbonic Anhydrase Cancer
    HCAIX-IN-2 (compound 9d) is a selective carbonic anhydrase inhibitor with the Ki values of 24.6 nM and 45.3 nM for hCA IX and hCA XII, respectively .
    HCAIX-IN-2
  • HY-161374
    Carbonic anhydrase inhibitor 20

    		Carbonic Anhydrase Cancer
    Carbonic anhydrase inhibitor 20 (compound 11) is an inhibitor of piperazinosulfonamide carbonic anhydrase (Carbonic Anhydrase). The Ki of Carbonic anhydrase inhibitor 20 for hCA I, hCA II, hCA IX, and hCA XII are 47.6 nM, 36.5 nM, 8.3 nM, and 2.7 nM respectively .
    Carbonic anhydrase inhibitor 20
  • HY-163268
    Carbonic anhydrase inhibitor 18

    		Carbonic Anhydrase Cancer
    Carbonic anhydrase inhibitor 18 (Compound 9) is a human carbonic anhydrase (hCA) isoform inhibitor, with Kis of 604.8, 333.6, 1.9 and 6.7 nM for hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 18 can be used for the research of cancer .
    Carbonic anhydrase inhibitor 18
  • HY-161286
    hCAXII-IN-8

    		Carbonic Anhydrase Cancer
    hCAXII-IN-8 (compound 5r) is a potent carbonic anhydrase hCA XII inhibitor .
    hCAXII-IN-8
  • HY-N2682A
    (E)-Dehydrodiconiferyl alcohol

    		Carbonic Anhydrase Cancer
    (E)-Dehydrodiconiferyl alcohol behaves as good hCA IX and hCA XII dual inhibitors . And (E)-Dehydrodiconiferyl alcohol suppresses the NF-κB nuclear translocation in connective tissue of healing area .
    (E)-Dehydrodiconiferyl alcohol
  • HY-161295
    hCAIX/XII-IN-10

    		Carbonic Anhydrase Cancer
    hCAIX/XII-IN-10 (compound DK-8) is a carbonic anhydrase inhibitor. hCAIX/XII-IN-10 has potent inhibitory activity against tumor-associated membrane-bound isoforms hCA IX and XII, with Ki values of 32.5 nM and 29.2 nM .
    hCAIX/XII-IN-10
  • HY-129986
    hCAI/II-IN-9

    		Others Others
    hCAI/II-IN-9 is a carbonic anhydrase inhibitor with inhibitory activity against human carbonic anhydrase isoforms I, II, IX, and XII. The inhibition constants (Ki) of hCAI/II-IN-9 for hCA I are in the range of 7.9-894 nM, for hCA II are in the range of 7.5-1645 nM, for hCA IX are in the range of 5.0-240 nM, and for hCA XII are in the range of 0.47-2.83 nM. hCAI/II-IN-9 may have potential applications in inhibiting a variety of pathologies involving these carbonic anhydrase isoforms .
    hCAI/II-IN-9
  • HY-159128
    hCAIX-IN-21

    		Carbonic Anhydrase Cancer
    hCAIX-IN-21 (compound 16c) is a potent hCAIX inhibitor with KI values of 5.2, 3.5, 12.6, 13600 nM for hCAIX, hCA II, hCA XII, hCA I, respectively. hCAIX-IN-21 inhibits cathepsin B enzyme activity .
    hCAIX-IN-21
  • HY-152141
    hCAII-IN-9

    		Carbonic Anhydrase Others
    hCAII-IN-9 is a potent carbonic anhydrase inhibitor with IC50s of 1.18 μM (hCA II), 0.17 μM (hCA IX), and 2.99 μM (hCA XII), respectively. hCAII-IN-9 has no blood-brain barrier permeability .
    hCAII-IN-9
  • HY-151472
    hCAIX/XII-IN-6

    		Carbonic Anhydrase Infection
    hCAIX/XII-IN-6 is an orally active carbonic anhydrase (CA) inhibitor. hCAIX/XII-IN-6 inhibits human CA isoforms hCA I, II, IV, IX, and XII with Ki values of 6697 nM, 2950 nM, 4093 nM, 4.1 nM and 7.7 nM, respectively. hCAIX/XII-IN-6 can be used for the research of rheumatoid arthritis (RA) .
    hCAIX/XII-IN-6
  • HY-159982
    SH7s

    		Carbonic Anhydrase Cancer
    SH7s is a potent carbonic anhydrases inhibitor, with Kis of 15.9 and 55.2 nM for hCA IX and hCA XII, respectively. SH7s is also a hypoxia-mediated chemo-sensitizing agent in colorectal cancer cells .
    SH7s
  • HY-155391
    hCA/Wnt/β-catenin-IN-1

    		Carbonic Anhydrase P-glycoprotein Wnt β-catenin Cancer
    hCA/Wnt/β-catenin-IN-1 (Compd 15) is an inhibitor of hCA (Ki: 33.6, 24.1, 6.8 nM for hCA II, hCA IX, hCA XII). hCA/Wnt/β-catenin-IN-1 reduces P-gp activity. hCA/Wnt/β-catenin-IN-1 also inhibits Wnt/β-catenin signaling pathway. hCA/Wnt/β-catenin-IN-1 inhibits cancer cell viability, including the NCI/ADR-RES DOX-resistant cell line .
    hCA/Wnt/β-catenin-IN-1
  • HY-162226
    Carbonic anhydrase inhibitor 19

    		Carbonic Anhydrase Others
    Carbonic anhydrase inhibitor 19 (compound 26a) inhibits the Glaucoma related isoforms hCA II and hCA XII with Kis of 9.4 nM and 6.7 nM, respectively. Carbonic anhydrase inhibitor 19 reveals an intraocular pressure (IOP) lowering effect .
    Carbonic anhydrase inhibitor 19
  • HY-150572
    CDK2-IN-11

    		CDK Carbonic Anhydrase Cancer
    CDK2-IN-11 (compound 9d) is a potent CDK2 inhibitor with an IC50 of 6.4 μM, and KI values of 23.4 nM, 56.3 nM and 44.3 nM for hCA II, hCA IX and hCA XII, respectively. CDK2-IN-11 can be used for researching anticancer .
    CDK2-IN-11
  • HY-159568
    hCAIX-IN-22

    		Carbonic Anhydrase Cancer
    hCAIX-IN-22 is a highly selective inhibitor of human carbonic anhydrase (hCA) isoform XII (Ki=9.7 nM) with anticancer activity .
    hCAIX-IN-22
  • HY-148135
    hCAI/II-IN-6

    		Carbonic Anhydrase Neurological Disease
    hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy .
    hCAI/II-IN-6
  • HY-150570
    Carbonic anhydrase inhibitor 14

    		Carbonic Anhydrase CDK Cancer
    Carbonic anhydrase inhibitor 14 (Compound 8b) is a carbonic anhydrase (CA) inhibitor with Ki values of 1203, 99.7, 9.4 and 27.7 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 14 can also inhibit CDK2 with an IC50 of 20.3 μM. Carbonic anhydrase inhibitor 14 shows antitumor activity .
    Carbonic anhydrase inhibitor 14
  • HY-168030
    hCAIX-IN-23

    		Apoptosis Ferroptosis Carbonic Anhydrase Reactive Oxygen Species Caspase Mitochondrial Metabolism Cancer
    hCAIX-IN-23 (Compound 27) is a human carbonic anhydrase (hCA) inhibitor with Ki values of 10.4 and 8.5 nM for hCA IX and hCA XII, respectively. In addition to inhibiting hCA activity, hCAIX-IN-23 releases NO, exhibiting dual antitumor activity. hCAIX-IN-23 induces apoptosis by regulating mitochondrial caspase activity and the ferroptosis pathway (ferroptosis) through the downregulation of hCA IX and iron-regulatory protein expression. hCAIX-IN-23 is useful for renal cancer research .
    hCAIX-IN-23
  • HY-147664
    hCAXII-IN-1

    		Carbonic Anhydrase Cancer
    These compounds show selective inhibition on tumor related subtypes HCA IX and XII, and are also considered as the leading molecules for the development of future cancer therapeutic drugs based on new mechanisms of action.
    hCAXII-IN-1
  • HY-162000
    hCAIX/XII-IN-13

    		Apoptosis Cancer
    hCAIX/XII-IN-13 is an inhibitor of human carbonic anhydrases (hCA). hCAIX/XII-IN-13 shows good inhibitory activity against the tumor-related CA subtypes IX and XII, with Ki values of 0.08 µM and 0.06 µM, respectively. Under hypoxic conditions, hCAIX/XII-IN-13 can restore the cytotoxicity of Doxorubicin (HY-15142A) on MCF-7 cells, increasing G2/M phase cell cycle arrest and apoptosis .
    hCAIX/XII-IN-13
  • HY-147663
    hCAIX-IN-6

    		Carbonic Anhydrase Cancer
    Compounds 6b and 14g showed significant inhibitory effect on tumor related subtype HCA IX with low nanomolar potency, while 6k was effective on HCA XII. Compounds 6b, 14g and 6k can be considered as the leading molecules for the development of future cancer therapeutic drugs based on new mechanisms of action.
    hCAIX-IN-6
  • HY-161686
    Carbonic anhydrase inhibitor 24

    		Carbonic Anhydrase Cancer
    Carbonic anhydrase inhibitor 24 (Compound 11) is a human carbonic anhydrase (carbonic anhydrase) inhibitor. Ki values of Carbonic anhydrase inhibitor 24 for hCAs IX and XII were 10.7 and 7.5 nM, respectively .
    Carbonic anhydrase inhibitor 24
  • HY-151630
    hCAIX-IN-16

    		Carbonic Anhydrase Cancer
    hCAIX-IN-16 (Compound 12d) is hCA IX inhibitor, with Ki values of 190.0 and 187.9 nM for hCA IX and hCA XII, respectively. hCAIX-IN-16 can arrest the cell cycle of breast cancer MDA-MB-468 in G0-G1 and S phase and induce apoptosis. hCAIX-IN-16 shows good broad-spectrum anticancer activity and can be used for cancer research .
    hCAIX-IN-16
  • HY-155271
    hCAXII-IN-7

    		Carbonic Anhydrase Others
    hCAXII-IN-7 (compound 6e) is a hCA XII inhibitor. hCAXII-IN-7 has BBB permeability. hCAXII-IN-7 induces 786-0, SF-539 and HS 578 T cells apoptotic .
    hCAXII-IN-7

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: